AG
ENTA icon

Algert Global’s Enanta Pharmaceuticals ENTA Stock Holding History

Algert Global’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,106
Closed -$133K – 1193
2025
Q3 		$133K Buy
+11,106
New +$88.7K ﹤0.01% 1074
2023
Q4 		– Sell
-29,364
Closed -$328K – 1161
2023
Q3 		$328K Hold
29,364
– – 0.02% 868
2023
Q2 		$628K Buy
29,364
+12,160
+71% +$358K 0.03% 763
2023
Q1 		$696K Buy
17,204
+724
+4% +$34.6K 0.03% 749
2022
Q4 		$767K Sell
16,480
-7,030
-30% -$320K 0.04% 671
2022
Q3 		$1.22M Sell
23,510
-5,510
-19% -$322K 0.07% 458
2022
Q2 		$1.37M Buy
29,020
+10,560
+57% +$573K 0.1% 346
2022
Q1 		$1.31M Buy
+18,460
New +$1.2M 0.09% 398
2019
Q3 		– Sell
-3,309
Closed -$279K – 385
2019
Q2 		$279K Sell
3,309
-9,877
-75% -$888K 0.1% 238
2019
Q1 		$1.26M Sell
13,186
-9,279
-41% -$832K 0.72% 29
2018
Q4 		$1.59M Buy
22,465
+4,543
+25% +$348K 0.44% 74
2018
Q3 		$1.53M Buy
17,922
+10,702
+148% +$1.07M 0.33% 113
2018
Q2 		$837K Buy
7,220
+150
+2% +$15K 0.17% 199
2018
Q1 		$572K Buy
+7,070
New +$544K 0.11% 237

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Algert Global's ENTA Position: Q4 2025 in Review

Algert Global sold out of Enanta Pharmaceuticals (ENTA) in Q4 2025, closing a stake of 11,106 shares — an estimated $133K sold.

Algert Global first reported a position in ENTA in Q1 2018 and held it in 14 quarters. The position peaked at $1.59M in Q4 2018. 131 funds tracked by Wall St. Rank hold ENTA as of Q4 2025.

  • Algert Global reported no remaining Enanta Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Algert Global sold 11,106 Enanta Pharmaceuticals shares in Q4 2025, an estimated $133K.
  • Algert Global first reported a position in Enanta Pharmaceuticals in Q1 2018 and held it in 14 quarters.
  • Algert Global's Enanta Pharmaceuticals position peaked at $1.59M in Q4 2018.
  • 131 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2025.

Based on Algert Global's 13F filing for Q4 2025, filed 17 Feb 2026.